Integrated Quantitative Investments LLC Invests $92,000 in Inogen, Inc. (NASDAQ:INGN)

Integrated Quantitative Investments LLC bought a new position in shares of Inogen, Inc. (NASDAQ:INGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 10,000 shares of the medical technology company’s stock, valued at approximately $92,000.

A number of other institutional investors have also recently bought and sold shares of the business. JPMorgan Chase & Co. raised its position in shares of Inogen by 2.7% in the third quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company’s stock valued at $8,692,000 after buying an additional 23,891 shares in the last quarter. Barclays PLC increased its stake in Inogen by 72.9% during the 3rd quarter. Barclays PLC now owns 55,508 shares of the medical technology company’s stock worth $539,000 after acquiring an additional 23,398 shares during the period. Geode Capital Management LLC raised its holdings in Inogen by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock valued at $5,377,000 after acquiring an additional 5,921 shares in the last quarter. Franklin Resources Inc. bought a new stake in shares of Inogen during the 3rd quarter valued at $139,000. Finally, State Street Corp grew its holdings in shares of Inogen by 2.8% during the 3rd quarter. State Street Corp now owns 511,018 shares of the medical technology company’s stock worth $4,957,000 after purchasing an additional 14,054 shares in the last quarter. Institutional investors own 89.94% of the company’s stock.

Inogen Stock Performance

Shares of INGN opened at $7.04 on Friday. Inogen, Inc. has a 52-week low of $6.14 and a 52-week high of $13.33. The firm has a market cap of $189.28 million, a price-to-earnings ratio of -3.13 and a beta of 1.16. The business’s fifty day moving average is $9.01 and its 200-day moving average is $9.39.

Analysts Set New Price Targets

INGN has been the subject of a number of analyst reports. StockNews.com downgraded Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Needham & Company LLC restated a “hold” rating on shares of Inogen in a research report on Wednesday, February 26th.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.